Raymond W. Urbanski

President at CSA, Inc.

Raymond W. Urbanski

Raymond W. Urbanski

President at CSA, Inc.

Overview
Career Highlights

CSA, Inc.
Applied Biosciences Corp.
GT Biopharma, Inc.

RelSci Relationships

3817

Number of Boards

2

Birthday

1960

Age

60

Relationships
RelSci Relationships are individuals Raymond W. Urbanski likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer & President at GT Biopharma, Inc.

Relationship likelihood: Strong

Founder at Applied Biosciences Corp.

Relationship likelihood: Strong

Co-Founder at Km Pharmaceutical Consulting LLC

Relationship likelihood: Strong

Chief Financial Officer at Applied Molecular Transport, Inc.

Relationship likelihood: Strong

Owner at Steven W. Weldon, P.A.

Relationship likelihood: Strong

Executive Vice President at Translational Research In Oncology

Relationship likelihood: Strong

President, Director at Applied Biosciences Corp.

Relationship likelihood: Strong

President-CBD Products at Applied Biosciences Corp.

Relationship likelihood: Strong

President & Director at Stony Hill Ventures Corp.

Relationship likelihood: Strong

Partner at DLA Piper

Relationship likelihood: Strong

Paths to Raymond W. Urbanski
Potential Connections via
Relationship Science
You
Raymond W. Urbanski
President at CSA, Inc.
Career History
President
Current
Chief Medical Officer, Vice President-Research & Development
Current
Chief Medical Officer & Vice President
2015 - 2017

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Our lead investigational product candidate, AFREZZA® (pronounced uh-FREZZ-uh) is a novel, ultra rapid-acting mealtime insulin therapy. AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. It is a drug-device combination product, consisting of AFREZZA inhalation powder pre-metered into single use dose cartridges and the light, discreet and easy-to-use AFREZZA inhaler. Because of its unique pharmacokinetic profile, AFREZZA may be a promising new therapy for patients with Type 1 and Type 2 diabetes, as it controls post meal-time glucose levels with less weight gain and lower risk of hypoglycemia. AFREZZA utilizes our proprietary Technosphere® formulation technology, which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Beyond convenience, we believe the key advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Raymond W. Urbanski. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Raymond W. Urbanski's profile does not indicate a business or promotional relationship of any kind between RelSci and Raymond W. Urbanski.